Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview
SCYNEXIS Inc expected to post a loss of 51 cents a share - Earnings Preview
SCYNEXIS Inc SCYX.OQ SCYX.O is expected to show a fall in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for SCYNEXIS Inc is for a loss of 51 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for SCYNEXIS Inc is $32.00, about 515.4% above its last closing price of $5.20
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -1.00 | -0.99 | -3.36 | Missed | -240.5 |
Dec. 31 2026 | 2.32 | 1.01 | 1.94 | Beat | 91.1 |
Sep. 30 2025 | -1.68 | -1.60 | -1.36 | Beat | 15 |
Jun. 30 2025 | -1.47 | -1.52 | -1.12 | Beat | 26.3 |
Mar. 31 2025 | -1.39 | -1.40 | -0.88 | Beat | 37.1 |
Dec. 31 2024 | -1.76 | -0.72 | Beat | 59.1 | |
Sep. 30 2024 | -0.55 | -0.59 | -0.48 | Beat | 18.9 |
Jun. 30 2024 | -1.63 | -1.62 | -2.40 | Missed | -48.5 |
This summary was machine generated August 7 at 22:04 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview